Pharmafile Logo

Cuttsy+Cuttsy awarded CPD Platinum by the IPA

Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation.

- PMLiVE

Platinum is only awarded to agencies who have reached gold level four years out of five and C+C have done it in their first four years of full membership of the IPA. In 2018 the agency team completed 905 hours of professional development vs. the 333 hours that agency needed to meet the IPA standard requirements.

On receiving the news Mathew Cutts, Co-Founder and Director spoke about the importance of the award ‘The workplace is evolving very quickly and attracting and retaining great people is no longer just about salary and a bonus. People are looking for many different aspects of employment, such as flexible working, having a career that makes a difference, progression and of course the chance to learn. This award is testament to the team and their thirst to want to continually improve it also evidences our commitment to the growth of individuals as well as the company’.

Kate McCabe, HR manager who is responsible for the initiative talked about what it takes to become a Platinum award winner. ‘Hard work and dedication, but more importantly, a commitment to truly investing in the belief that developing your team will not only develop and grow the business but motivate and retain the best people. Ultimately, providing a first-class service to your clients and for us most importantly, patients.

This content was provided by Cuttsy + Cuttsy

Company Details

 Latest Content from  Cuttsy + Cuttsy 

Permission to pause: making treatment breaks part of the cancer care conversation

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

A seat at the table: what the EU HTA reforms really ask of patient involvement

The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.

Why faster trials make participant understanding more important than ever

As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.

Older trial participants reject bad design, not technology

Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.

5 key takeaways from the Patient Centricity and Engagement Conference

Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.

It’s time to stop calling adverse events ‘manageable’

A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.

The value: why localisation pays off across global trials

Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.

The solution: Good localisation doesn’t feel translated

Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.

Healthcare information is becoming easier to access. Trust isn’t.

Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.

It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment

ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.